Verona Pharma (VRNA)
(Delayed Data from NSDQ)
$34.98 USD
+1.05 (3.09%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $34.97 -0.01 (-0.03%) 7:58 PM ET
2-Buy of 5 2
F Value F Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
VRNA 34.98 +1.05(3.09%)
Will VRNA be a Portfolio Killer in November?
Zacks Investment Research is releasing its prediction for VRNA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for VRNA
Recent Price Trend in Verona Pharma (VRNA) is Your Friend, Here's Why
Zacks Industry Outlook Highlights Exelixis, Blueprint Medicines, CRISPR, Amicus and Verona Pharma
VRNA: What are Zacks experts saying now?
Zacks Private Portfolio Services
5 Biotech Stocks Likely to Outperform as Industry Prospects Look Bright
Wall Street Analysts Think Verona Pharma (VRNA) Could Surge 25.25%: Read This Before Placing a Bet
Verona Pharma (VRNA) Is a Great Choice for 'Trend' Investors, Here's Why
Other News for VRNA
Verona Pharma reports Q3 results
Verona Pharma Q3 2024 Earnings Preview
Verona Pharma PLC (VRNA) Q3 2024 Earnings Report Preview: What To Expect
Insider Sale: President and CEO David Zaccardelli Sells Shares of Verona Pharma PLC
Insider Sale: CFO Mark Hahn Sells 144,560 Shares of Verona Pharma PLC (VRNA)